Is SGYP a pharma takeover scam that went south??

Discussion in 'Synergy Pharmaceuticals' started by anonymous, Jan 26, 2018 at 1:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I have always operated from the assumption that the Jacob/Cerrone/Biaggio ring were scam artists (let's not forget the distinguished Chief Scientic Officer, Kunwar Shahlubhai, whose scientific accomplishments are a mystery.) But if you're going to assemble a pharma scam, one of the essential ingredients is someone with a PhD from the University of Baroda. It's all of a piece with their prior ventures, Callisto Pharmaceuticals (defunct),ContraVir (pink sheets), Trovagene (pink sheets) and the one they sold to B-M, defrauding them out of $2 billion. Their trail results were iffy at best and if you take into account their previous record with concocting fraudulent trial results for Inhibitex, no one would buy a used car from these guys. (Their trials for the Inhibitex drug , a supposed treatment for Hep C, showed no adverse reactions. When B-M ran the trials, they found that the drug killed people and wrote the whole $2 billion investment off.) These guys are crooks. When Shahlubhai bailed, you knew this was over. When Brancaccio, Jacob's bagman, bailed, it confirmed this. They are onto the next scam, right upstairs at 420 Lexington Ave., Rasna Thereapeutics, a company which Kevin (aka Life Sciences Millennial) has already started to pump. No, this Trulance is not "best-in-class" or “superior” to Linzess..the fact that script refills are pitiful shows that it doesn't work very well. After all the hoopla about destroying Linzess, they are losing $50 million a quarter to generate a pathetic 2,200 scripts a week. Net net: You've been scammed. These guys are a pharmaceutical company only in the sense that Bernie Madoff was an investment advisor.
     

  2. anonymous

    anonymous Guest

    I wish you would have posted this a year ago. I figured it out over the summer when Shahmu announced he was leaving, that was a huge red flag.
     
  3. anonymous

    anonymous Guest

    Trulance is a me-too and the coverage is just the worst
     
  4. anonymous

    anonymous Guest

    Prior Auth fatigue starting to set in
     
  5. anonymous

    anonymous Guest

    Need to start dosing via rectum. Suppository approach for the win!
     
  6. anonymous

    anonymous Guest

    Textbook example of bad management
     
  7. anonymous

    anonymous Guest

    The only people that post on cafepharma are generally people who are shorting a stock (initial poster) or disgruntled reps who can’t find success because they have always been subpar sales reps but hid out in the weeds.

    Trulance holds a strong market share with specialists. Ask patients who have failed everything there thoughts on how well Trulance worked for them. Ask a patient who couldn’t get off the toilet because Linzess’ side effect profile was just too much and they got switched to Trulance.

    Trulance is best in class and will win in the long run. How long that takes is up to the Salesforce and salesforce alone. Strong leadership at the regional Sales level and sales management level will be critical, but inevitably it will be up to the person in the field. The product is too good and will remain a solution for suffering patients for decades to come.

    My apologies that you weren’t able to flip stock at a 300% gain already, that will never occur in the near future but down the road the people who work hard and stick around and tow the line will make this product known to all cic/ibs-c sufferers....and shareholders.
     
  8. anonymous

    anonymous Guest

    Poster #7 is a deranged pumper of this stock, presumably underwater with a high cost basis, willing to post anything on social media to make company look great. Too many old men on stocktwits gambling their retirement accounts on this stock. It’s a fantasy for these types of investors to be involved in a Wall Street acquisition, of a stock they own, and make 400% return. Synergy isn’t for sale and never was, learn the history.
     
  9. anonymous

    anonymous Guest

    Lol. The idea that execs wouldn't want to sell and profit is ludicrous. Atleast justify your statements rather than say they will never sell. The reality of the situation is they will most likely get put in a position where they will have to sell.
     
  10. anonymous

    anonymous Guest

    Totally agree, what a stupid post by OP. Must be one of the weak sauce managers there.
     
  11. anonymous

    anonymous Guest

    The company is groomed for acquisition moron.
     
  12. Cindie

    Cindie Guest

     
  13. anonymous

    anonymous Guest

    That’s the way Synergy is giving it to us.
    We’re not winning.
     
  14. anonymous

    anonymous Guest

    Well put. I have absolutely taken it up the rectum having come to this sh** hole of a company.
     
  15. anonymous

    anonymous Guest

    Poor management and direction killing this company
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    so accuate. They shuffle the deck and bring in the old boys from past occasionally but Mgnt was all wanna beees at Salix and given a chance here to lead but were mislead themselves. Wake up to the facts and our own fault for taking the job and believing the no experience wanna bees.. set up to sell or fail.....it failed!
     
  18. anonymous

    anonymous Guest

    Yep. We were all suckers. My gut kept telling me no, but my brain said this would be a good opportunity to get in on the ground floor of a good company.
    We got played like a fiddle.
     
  19. anonymous

    anonymous Guest

    Great synopsis of the scam. Never trust a swammy, salami, baloney.
    Smoke and mirrors. Made Houdini look like an amateur.
     
  20. anonymous

    anonymous Guest

    A lot of us see clearly now. We were suckered and we’re pissed off. I left a great job to work for idiots. This “launch” is such a stupid waste of money too. The thought of senior leaders getting on the stage and lying to us again makes me barf.